Managing Director and Chief Executive Officer, Spinifex Pharmaceuticals
| Role | Organisation | Sources |
|---|---|---|
| Managing Director and Chief Executive Officer | Spinifex Pharmaceuticals | GBS Ventures (3 Aug 2006), GBS Ventures (26 Jul 2005) |
Stories naming Dr Michael Thurn. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Perth biotech PharmAust appointed Dr Michael Thurn as chief executive and reported positive urinary biomarker findings from its motor neurone disease trial of drug candidate MPL.
Spinifex Pharmaceuticals won a $1.67 million federal Commercial Ready grant to advance its neuropathic pain drug, after a $3.25 million syndicate raise the previous July; it was spun out of the University of Queensland.
University of Queensland spinout Spinifex Pharmaceuticals landed $3.25 million from Symbiosis, GBS Venture Partners and Uniseed to advance its neuropathic pain therapy toward toxicology testing.
Also GBS Ventures·GBS Ventures·clinicalleader.com·bionity.com